Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF antiviral strategy study in treatment-naive and previously treated chronic hepatitis B
ChiCTR2100044806Phase 4Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide and entecavir in Chronic Hepatitis B (CHB) (2 cohorts), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: HBV DNA. Started Apr 2021; status: recruiting.
02
Drugs
tenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100044806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044806.